ClinicalTrials.gg
CompletedNCT02990325Updated Mar 31, 2023Results posted

A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults

A Phase 1/2 interventional study of ABX464 150mg and ABX464 50mg in HIV Infections and Health Volunteers, sponsored by Abivax S.A.. Completed at 1 site in Spain. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-31.

Sponsored by Abivax S.A. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 261 studies in HIV Infections with a site in Spain — 10 open to participants now, 20 under way, 7 of them phase 3. HIV Infections · Spain.

Enrollment
169th of 229
36 · median 99
Started
2017
with 10 others
Phase 1/2
6 of 261
none open now
Registered
194th of 261
by date

Among the 261 studies in HIV Infections with a site in Spain, this one is the 169th largest by enrollment of the 229 interventional ones that give a count, is one of 11 that started in 2017, is one of 6 in phase 1/2, and was the 194th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

10 of the 261 studies in HIV Infections with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 261 studies in HIV Infections with a site in Spain, or all of them as a file.
02

Study summary

The purpose of the ABX464-005 study is to characterize the systemic and mucosal immunological sequelae associated with exposure to ABX464 and to explore selected immunological endpoints, compartmental pharmacokinetics, and pharmacodynamics.

Read the detailed description

The purpose of the ABX464-005 study is to characterize the systemic and mucosal immunological sequelae associated with exposure to ABX464 and to explore selected immunological endpoints, compartmental pharmacokinetics, and pharmacodynamics. The site will screen and enroll 12 HIV-infected subjects who will receive 150 mg ABX464 orally once daily for 28 days (Cohort 1). Following completion of this cohort a further 24 subjects will be enrolled: 12 HIV-uninfected subjects will receive 50 mg ABX464 orally once daily for 28 days (Cohort 2) and 12 HIV-infected subjects (Cohort 3) who will 50 mg ABX464 orally once daily for 84 days.

03

Conditions studied

  • HIV Infections
  • Health Volunteers

Browse trials for

Keywords

  • ABX464, HIV infection
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males aged 18-65 years;
  • Subjects with adequate hematological and biochemical laboratory parameters
  • Subjects should be able and willing to comply with study visits and procedures as per protocol;
  • Subjects should understand, sign and date the written voluntary form at the screening visit prior to any protocol-specific procedures being performed;
  • Subjects must agree to use in addition to the condom, a second highly effective method (one for the subject and one for the partner) of (defined as per the Clinical Trials Facilitation and Coordination Group (CTFG) Guidance).

For positive Subjects

  • Subjects with a positive HIV-1 serology at any time before the study entry.
  • Subjects treated for at least 12 months prior to screening with Dolutegravir or Raltegravir combined with either Tenofovir + Emtricitabine (TDF/FTC) or Abacavir + Lamivudine (ABC/3TC);
  • Subjects with HIV plasma viral load ≤ 50 copies/mL during the 6 months prior to screening with a maximum of 2 blips ≤ 1000 copies during this period;
  • Subjects' HIV-1 plasma viral load to be ≤ 100,000 copies/mL at any time beyond 6 months after the estimated date of primary infection;

Exclusion criteria

Exclusion Criteria:

  • History of allergic disease, anaphylaxis or reactions likely to be triggered or exacerbated by any component of products;
  • Acute or chronic infectious disease other than infection (include but not limited to viral hepatitis such as , , active tuberculosis, active syphilis [i.e. currently treated].
  • Acute, chronic or history of pulmonary, cardiovascular, gastrointestinal, hepatic, pancreatic or renal functional abnormality, encephalopathy, neuropathy or unstable Central Nervous System (CNS) pathology, angina or cardiac arrhythmias, or any other clinically significant medical problems as determined by physical examination and/or laboratory screening tests and/or medical history;
  • Severe hepatic impairment;
  • Acute, chronic or history of immunodeficiency or disease other than HIV infection;
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    ABX464 150mg

    ABX464, 50mg per Capsule Three Capsules per day for 28 days

    Drug: ABX464 150mg

  • Experimental
    ABX464 50mg for 28 days

    ABX464, 50mg per Capsule One Capsule per day for 28 days

    Drug: ABX464 50mg

  • Experimental
    ABX464 50mg for 84 days

    ABX464, 50mg per Capsule One Capsule per day for 84 days

    Drug: ABX464 50mg

Interventions

  • ABX464 given orally at 150 mg per day from Day 0 to Day 28 (Cohort 1/ HIV infected subjects)

  • ABX464 given orally at 50 mg per day from Day 0 to Day 28 (Cohort 2 / non HIV infected subjects)

  • ABX464 given orally at 50 mg per day from Day 0 to Day 84 (Cohort 3 / HIV infected subjects)

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of ABX464 in Sera

    Pharmacokinetic parameters

    Time frame: Day 1, Day 28 and Day 84

  2. Maximum Observed Concentration (Cmax) of ABX464 in Sera

    Pharmacokinetic parameters

    Time frame: Day 1, Day 28 and day 84

  3. Area Under the Curve (AUC) of ABX464 Metabolite (ABX464-N-Glucuronide) in Sera

    Pharmacokinetics parameters

    Time frame: Day 1, Day 28 and Day 84

  4. Maximum Observed Concentration (Cmax) of ABX464 Metabolite (ABX464-N-Glucuronide) in Sera

    Pharmacokinetic parameters

    Time frame: Day 1, Day 28 and Day 84

  5. Maximum Observed Concentration (Cmax) of ABX464 in Peripheral Blood Mononuclear Cells (PBMC)

    Pharmacokinetic parameters

    Time frame: Day 1, Day 28 and Day 84

  6. Area Under the Curve (AUC) of ABX464 in Peripheral Blood Mononuclear Cells (PBMC)

    Pharmacokinetic parameters

    Time frame: Day 1, Day 28 and Day 84

  7. Maximum Observed Concentration (Cmax) of ABX464 Metabolite (ABX464-N-Glucuronide) in Peripheral Blood Mononuclear Cells (PBMC)

    Pharmacokinetic parameters

    Time frame: Day 1, Day 28 and Day 84

  8. Area Under the Curve (AUC) of ABX464 Metabolite (ABX464-N-Glucuronide) in Peripheral Blood Mononuclear Cells (PBMC)

    Pharmacokinetic parameters

    Time frame: Day 1, Day 28 and Day 84

  9. Concentration of ABX464 in Rectal Tissue (Measured Only at Pre-infusion Timepoint)

    Pharmacokinetic parameters

    Time frame: Day 1, Day 28, Day 56, Day 84 and Day 112

  10. Concentration of ABX464 Metabolite (ABX464-N-Glucuronide) in Rectal Tissue (Measured Only at Pre-infusion Timepoint)

    Pharmacokinetic parameters

    Time frame: Day 1, Day 28, Day 56, Day 84 and Day 112

Secondary outcomes

  1. Mean Change From Baseline in Plasma Viral Load (Ultrasensitive Assay)

    Viral Load Assessments (HIV-1 RNA copies/ml)

    Time frame: Day 28, Day 56, Day 84 and Day 112

  2. CD4+ Counts (Cell/mm^3)

    T-cell determinations

    Time frame: Day 28, Day 35, Day 56, Day 84, Day 91 and Day 112

  3. Total HIV-1 DNA Reservoir in Peripheral Blood Mononuclear Cells (PBMC)

    HIV reservoir cells (CD4+)

    Time frame: Day 28, Day 56, Day 84 and Day 112

07

Results

Posted Mar 31, 2023

Participant flow

Participant flow — Overall Study
MilestoneABX464 150mgABX464 50mg for 28 DaysABX464 50mg for 84 Days
Started111213
Completed111213
Not completed000

Outcome measures

PrimaryArea Under the Curve (AUC) of ABX464 in Sera

Pharmacokinetic parameters

Time frame:
Day 1, Day 28 and Day 84
Reported as:
Geometric mean · ng*h/mL
Area Under the Curve (AUC) of ABX464 in Sera
ng*h/mLABX464 150mgABX464 50mg for 28 DaysABX464 50mg for 84 Days
Day 1306.0 ± 46.563.7 ± 39.963.7 ± 77.4
Day 28119.8 ± 48.717.8 ± 60.930.3 ± 68.2
Day 84——28.9 ± 66.8
PrimaryMaximum Observed Concentration (Cmax) of ABX464 in Sera

Pharmacokinetic parameters

Time frame:
Day 1, Day 28 and day 84
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax) of ABX464 in Sera
ng/mLABX464 150mgABX464 50mg for 28 DaysABX464 50mg for 84 Days
Day 1106.1 ± 54.523.1 ± 45.224.5 ± 75.5
Day 2850.9 ± 57.19.3 ± 60.313.0 ± 76.0
Day 84——15.6 ± 65.6
PrimaryArea Under the Curve (AUC) of ABX464 Metabolite (ABX464-N-Glucuronide) in Sera

Pharmacokinetics parameters

Time frame:
Day 1, Day 28 and Day 84
Reported as:
Geometric mean · ng*h/mL
Area Under the Curve (AUC) of ABX464 Metabolite (ABX464-N-Glucuronide) in Sera
ng*h/mLABX461 150mgABX464 50mg for 28 DaysABX464 50mg for 84 Days
Day 150115.8 ± 41.58282.3 ± 37.011209.6 ± 66.5
Day 2848605.0 ± 40.64800.6 ± 37.013308.8 ± 62.5
Day 84——14588.2 ± 58.3
PrimaryMaximum Observed Concentration (Cmax) of ABX464 Metabolite (ABX464-N-Glucuronide) in Sera

Pharmacokinetic parameters

Time frame:
Day 1, Day 28 and Day 84
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax) of ABX464 Metabolite (ABX464-N-Glucuronide) in Sera
ng/mLABX464 150mgABX464 50mg for 28 DaysABX464 50mg for 84 Days
Day 19918.2 ± 33.51626.8 ± 36.92036.2 ± 62.8
Day 287011.1 ± 37.5695.9 ± 38.61705.5 ± 71.8
Day 84——2150.6 ± 56.1
PrimaryMaximum Observed Concentration (Cmax) of ABX464 in Peripheral Blood Mononuclear Cells (PBMC)

Pharmacokinetic parameters

Time frame:
Day 1, Day 28 and Day 84
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax) of ABX464 in Peripheral Blood Mononuclear Cells (PBMC)
ng/mLABX464 150mgABX464 50mg for 28 DaysABX464 50mg for 84 Days
Day 1463.3 ± 55.0209.4 ± 54.4203.8 ± 81.0
Day 28247.8 ± 75.776.4 ± 51.772.3 ± 82.9
Day 84——73.6 ± 57.5
PrimaryArea Under the Curve (AUC) of ABX464 in Peripheral Blood Mononuclear Cells (PBMC)

Pharmacokinetic parameters

Time frame:
Day 1, Day 28 and Day 84
Reported as:
Geometric mean · ng*h/mL
Area Under the Curve (AUC) of ABX464 in Peripheral Blood Mononuclear Cells (PBMC)
ng*h/mLABX464 150mgABX464 50mg for 28 DaysABX464 50mg for 84 Days
Day 11120.7 ± 52.6594.2 ± 53.2481.5 ± 78.9
Day 28522.4 ± 49.2156.0 ± 51.8151.6 ± 74.3
Day 84——144.9 ± 48.6
PrimaryMaximum Observed Concentration (Cmax) of ABX464 Metabolite (ABX464-N-Glucuronide) in Peripheral Blood Mononuclear Cells (PBMC)

Pharmacokinetic parameters

Time frame:
Day 1, Day 28 and Day 84
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax) of ABX464 Metabolite (ABX464-N-Glucuronide) in Peripheral Blood Mononuclear Cells (PBMC)
ng/mLABX464 150mgABX464 50mg for 28 DaysABX464 50mg for 84 Days
Day 1585.5 ± 60.339.7 ± 90.5230.0 ± 153.9
Day 28491.5 ± 73.035.6 ± 85.7125.1 ± 86.1
Day 84——153.3 ± 49.4
PrimaryArea Under the Curve (AUC) of ABX464 Metabolite (ABX464-N-Glucuronide) in Peripheral Blood Mononuclear Cells (PBMC)

Pharmacokinetic parameters

Time frame:
Day 1, Day 28 and Day 84
Reported as:
Geometric mean · ng*h/mL
Area Under the Curve (AUC) of ABX464 Metabolite (ABX464-N-Glucuronide) in Peripheral Blood Mononuclear Cells (PBMC)
ng*h/mLABX464 150mgABX464 50mg for 28 DaysABX464 50mg for 84 Days
Day 12133.7 ± 42.239.2 ± 186.7835.3 ± 116.0
Day 282212.3 ± 58.835.0 ± 210.1697.5 ± 92.0
Day 84——766.5 ± 57.4
PrimaryConcentration of ABX464 in Rectal Tissue (Measured Only at Pre-infusion Timepoint)

Pharmacokinetic parameters

Time frame:
Day 1, Day 28, Day 56, Day 84 and Day 112
Reported as:
Mean · ng/mL
Concentration of ABX464 in Rectal Tissue (Measured Only at Pre-infusion Timepoint)
ng/mLABX464 150mgABX464 50mg for 28 DaysABX464 50mg for 84 Days
Day 10.0 ± 0.000.0 ± 0.000.0 ± 0.00
Day 280.1 ± 0.110.1 ± 0.190.1 ± 0.13
Day 560.0 ± 0.00——
Day 84——0.1 ± 0.13
Day 112——0.0 ± 0.00
PrimaryConcentration of ABX464 Metabolite (ABX464-N-Glucuronide) in Rectal Tissue (Measured Only at Pre-infusion Timepoint)

Pharmacokinetic parameters

Time frame:
Day 1, Day 28, Day 56, Day 84 and Day 112
Reported as:
Mean · ng/mL
Concentration of ABX464 Metabolite (ABX464-N-Glucuronide) in Rectal Tissue (Measured Only at Pre-infusion Timepoint)
ng/mLABX464 150mgABX464 50mg for 28 DaysABX464 50mg for 84 Days
Day 10.0 ± 0.000.1 ± 0.080.0 ± 0.00
Day 280.1 ± 0.040.1 ± 0.110.1 ± 0.09
Day 560.0 ± 0.00——
Day 84——0.2 ± 0.11
Day 112——0.0 ± 0.00
SecondaryMean Change From Baseline in Plasma Viral Load (Ultrasensitive Assay)

Viral Load Assessments (HIV-1 RNA copies/ml)

Time frame:
Day 28, Day 56, Day 84 and Day 112
Reported as:
Mean · copies/mL
Mean Change From Baseline in Plasma Viral Load (Ultrasensitive Assay)
copies/mLABX464 150mgABX464 50mg
Day 28-0.9 (-1.9 to 0.1)-2.0 (-4.3 to 0.2)
Day 56-0.4 (-1.5 to 0.7)—
Day 84—-0.9 (-3.0 to 1.2)
Day 112—-1.1 (-3.7 to 1.5)
SecondaryCD4+ Counts (Cell/mm^3)

T-cell determinations

Time frame:
Day 28, Day 35, Day 56, Day 84, Day 91 and Day 112
Reported as:
Mean · cells/mm^3
CD4+ Counts (Cell/mm^3)
cells/mm^3ABX464 150mgABX464 50mg
Day 28-130.6 (-217.5 to -43.6)-34.6 (-167.7 to 98.5)
Day 35-125.6 (-266.2 to 15.1)—
Day 5629.6 (-202.4 to 261.5)—
Day 84—8.3 (-90.2 to 106.9)
Day 91—23.3 (-122.5 to 169.0)
Day 112—161.8 (59.5 to 264.2)
SecondaryTotal HIV-1 DNA Reservoir in Peripheral Blood Mononuclear Cells (PBMC)

HIV reservoir cells (CD4+)

Time frame:
Day 28, Day 56, Day 84 and Day 112
Reported as:
Mean · copies/10^6 cells
Total HIV-1 DNA Reservoir in Peripheral Blood Mononuclear Cells (PBMC)
copies/10^6 cellsABX464 150mgABX464 50mg
Day 28-86.8 (-172.2 to -1.3)22.3 (-21.7 to 66.4)
Day 56-37.1 (-139.1 to 64.9)—
Day 84—10.8 (-55.3 to 76.9)
Day 112—95.6 (26.1 to 165.0)

Adverse events

Collected over From baseline up to 112 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABX464 150mg0/11 (0%)0/11 (0%)9/11 (81.8%)
ABX464 50mg for 28 Days0/12 (0%)0/12 (0%)3/12 (25%)
ABX464 50mg for 84 Days0/13 (0%)0/13 (0%)7/13 (53.8%)
Most frequent other events
Showing 10 of 25
Most frequent other events
EventABX464 150mgABX464 50mg for 28 DaysABX464 50mg for 84 Days
HeadacheNervous system disorders8/112/124/13
Back painMusculoskeletal and connective tissue disorders4/110/121/13
MyalgiaMusculoskeletal and connective tissue disorders4/110/120/13
NauseaGastrointestinal disorders4/110/120/13
Abdominal painGastrointestinal disorders2/110/122/13
DiarrhoeaGastrointestinal disorders1/110/122/13
AsthemiaGeneral disorders1/110/120/13
HyperamylasaemiaMetabolism and nutrition disorders1/110/120/13
HyperlipaseamiaMetabolism and nutrition disorders1/110/120/13
InsomniaPsychiatric disorders1/110/120/13

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ABX464 150 mg Capsules for 28 DaysABX464 50 mg Capsules for 28 DaysABX464 50 mg Capsules for 84 DaysTotal
<=18 years0000
Between 18 and 65 years11121336
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)ABX464 150 mg Capsules for 28 DaysABX464 50 mg Capsules for 28 DaysABX464 50 mg Capsules for 84 DaysTotal
Female0000
Male11121336
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ABX464 150 mg Capsules for 28 DaysABX464 50 mg Capsules for 28 DaysABX464 50 mg Capsules for 84 DaysTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White11121336
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)ABX464 150 mg Capsules for 28 DaysABX464 50 mg Capsules for 28 DaysABX464 50 mg Capsules for 84 DaysTotal
Spain11121336
08

Study locations

1 site
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Catalogna 08916, Spain
09

References and documents

Publications

  • Moron-Lopez S, Bernal S, Wong JK, Martinez-Picado J, Yukl SA. ABX464 Decreases the Total Human Immunodeficiency Virus (HIV) Reservoir and HIV Transcription Initiation in CD4+ T Cells From Antiretroviral Therapy-Suppressed Individuals Living With HIV. Clin Infect Dis. 2022 Jun 10;74(11):2044-2049. doi: 10.1093/cid/ciab733. PubMed 34436569 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Dec 2018, 21 months.

Results were first posted in Mar 2023, 4 years 3 months after primary completion.

Of 42 phase 1/2 interventional studies under HIV Infections, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 73. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2016
First posted
Dec 13, 2016
StartActual
Mar 27, 2017
Primary completionActual
Dec 27, 2018
CompletionActual
Oct 21, 2019
Results first posted
Mar 31, 2023
Last update
Mar 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02990325
Lead sponsor
Abivax S.A.
Responsible party
Sponsor
First posted
Dec 13, 2016
Start date
Mar 27, 2017
Primary completion
Dec 27, 2018
Completion
Oct 21, 2019
Results posted
Mar 31, 2023
Last update
Mar 31, 2023

Study contacts

Paul GINESTE, PhD
study director · Abivax S.A.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABX464

Start the discussion